Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 9/20 | 0.76 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL683537 | 0.90 | ACE (0.81) | ACELMNASMN1; SMN2 | |
| SCHEMBL7266938 | 0.90 | ACE (0.81) | ACELMNASMN1; SMN2 | |
| SCHEMBL14039757 | 0.87 | ACE (0.86) | ACELMNASMN1; SMN2 | |
| Lisinopril Anhydrous SCHEMBL649165 | 0.87 | ACE (1.00) | ACELMNASMN1; SMN2 | |
| Lisinopril Anhydrous SCHEMBL7268245 | 0.87 | ACE (1.00) | ACELMNASMN1; SMN2 | |
| Lisinopril Anhydrous SCHEMBL24062681 | 0.87 | ACE (1.00) | ACELMNASMN1; SMN2 | |
| Lisinopril Anhydrous SCHEMBL15680 | 0.87 | ACE (1.00) | ACELMNASMN1; SMN2 | |
| Lisinopril Anhydrous SCHEMBL7276347 | 0.87 | ACE (1.00) | ACELMNASMN1; SMN2 | |
| Lisinopril Anhydrous SCHEMBL156900 | 0.87 | ACE (1.00) | ACELMNASMN1; SMN2 | |
| Lisinopril Anhydrous SCHEMBL18712916 | 0.87 | ACE (1.00) | ACELMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070093664-A1 | Process for the production of lisinopril | ECZACIBASI-ZENTIVA KIMYASAL URUNLER SANAYI VE TICARET A.S. (TR) | 2007-04-26 | — | — | US | claimed |
| EP-1513868-B1 | PROCESS FOR THE PRODUCTION OF LISINOPRIL | EOS ECZACIBASI OZGUN KIMYASAL (TR) | 2006-08-09 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093664-A1 | Process for the production of lisinopril | ACE, LOX, AGT | ACE 1/4885LMNA 222/4885SMN1; SMN2 2164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.